Inhibikase Therapeutics (IKT) Form 3 Inhibikase Therapeutics / Milton H. Werner ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Werner Milton H.

(Last) (First) (Middle)

3350 RIVERWOOD PARKWAY SE, SUITE 1900

(Street)

ATLANTA GA 30339

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/22/2020

3. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
President and CEO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,244,938(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	06/01/2011	06/01/2021	Common Stock	43,707(2)	0.38(3)	D
Stock Option (right to buy)	(4)	06/01/2023	Common Stock	21,853(2)	2.02(3)	D
Stock Option (right to buy)	(5)	03/01/2025	Common Stock	21,853(2)	2.02(3)	D
Stock Option (right to buy)	(6)	11/01/2025	Common Stock	21,853(2)	2.31(3)	D
Stock Option (right to buy)	(7)	11/01/2026	Common Stock	21,853(2)	2.31(3)	D
Stock Option (right to buy)	(8)	11/01/2027	Common Stock	21,853(2)	2.31(3)	D
Stock Option (right to buy)	(9)	11/01/2028	Common Stock	21,853(2)	4.79(3)	D
Stock Option (right to buy)	(10)	11/01/2029	Common Stock	21,853(2)	5.57(3)	D

Explanation of Responses:

1. The number of shares has been adjusted to reflect a one-for-1.14396 reverse stock split of the Issuer's common stock effected on August 24, 2020 (the "Reverse Split").

2. The number of shares has been adjusted to reflect the Reverse Split and excludes fractional shares resulting from the Reverse Split, which shall be paid in cash upon exercise.

3. The exercise price has been adjusted to reflect the Reverse Split.

4. The option vested in twelve equal monthly installments beginning on June 1, 2013.

5. The option vested in twelve equal monthly installments beginning on March 1, 2015.

6. The option vested in twelve equal monthly installments beginning on November 1, 2015.

7. The option vested in twelve equal monthly installments beginning on November 1, 2016.

8. The option vested in twelve equal monthly installments beginning on November 1, 2017.

9. The option vested in twelve equal monthly installments beginning on November 1, 2018.

10. The option vested in twelve equal monthly installments beginning on November 1, 2019.

	/s/ Milton H. Werner	12/22/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.